Evidence map›Paper›PMID 34206739›Full record

ReviewCells2021

Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.

Adrian Mor, Anna Tankiewicz-Kwedlo, Anna Krupa, Dariusz Pawlak

Abstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Gut microbes · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Immune-proteo-metabolomic changes link to Aβ and tau pathology in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adrian MorDepartment of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.ORCID 0000-0002-1308-7323
Anna Tankiewicz-KwedloDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.
Anna KrupaDepartment of Internal Medicine and Metabolic, Medical University of Bialystok, M. Skłodowskiej-Curie 24a, 15-276 Bialystok, Poland.
Dariusz PawlakDepartment of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.ORCID 0000-0002-3751-0608

Funding

Uniwersytet Medyczny w Białymstoku SUB/1/DN/20/001/2228
6 · The paper itself

Abstract

Neurodegenerative disorders are chronic and life-threatening conditions negatively affecting the quality of patients' lives. They often have a genetic background, but oxidative stress and mitochondrial damage seem to be at least partly responsible for their development. Recent reports indicate that the activation of the kynurenine pathway (KP), caused by an activation of proinflammatory factors accompanying neurodegenerative processes, leads to the accumulation of its neuroactive and pro-oxidative metabolites. This leads to an increase in the oxidative stress level, which increases mitochondrial damage, and disrupts the cellular energy metabolism. This significantly reduces viability and impairs the proper functioning of central nervous system cells and may aggravate symptoms of many psychiatric and neurodegenerative disorders. This suggests that the modulation of KP activity could be effective in alleviating these symptoms. Numerous reports indicate that tryptophan supplementation, inhibition of KP enzymes, and administration or analogs of KP metabolites show promising results in the management of neurodegenerative disorders in animal models. This review gathers and systematizes the knowledge concerning the role of metabolites and enzymes of the KP in the development of oxidative damage within brain cells during neurodegenerative disorders and potential strategies that could reduce the severity of this process.

Indexed as

Metabolic Networks and PathwaysOxidative StressAnimalsHumansKynurenineMetabolomeNeurodegenerative DiseasesReceptors, Aryl HydrocarbonKynurenineReceptors, Aryl Hydrocarbon3-hydroxykynurenineexcitotoxicitykynureninekynurenine pathwayneurodegenerative disordersoxidative stressquinolinic acidreactive oxygen speciestryptophan

Identifiers

PMID34206739
PMCPMC8306609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.